JP6757252B2 - 血漿カリクレイン系バイオマーカーを決定するためのアッセイ - Google Patents

血漿カリクレイン系バイオマーカーを決定するためのアッセイ Download PDF

Info

Publication number
JP6757252B2
JP6757252B2 JP2016549206A JP2016549206A JP6757252B2 JP 6757252 B2 JP6757252 B2 JP 6757252B2 JP 2016549206 A JP2016549206 A JP 2016549206A JP 2016549206 A JP2016549206 A JP 2016549206A JP 6757252 B2 JP6757252 B2 JP 6757252B2
Authority
JP
Japan
Prior art keywords
pkal
plasma
sample
activity
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016549206A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016536012A5 (cg-RX-API-DMAC7.html
JP2016536012A (ja
Inventor
セックストン，ダニエル，ジェー．
フォーセッテ，ライアン
ケニストン，ジョン，エー．
コンリー，グレゴリー，ピー．
ニクソン，アンドリュー
テノア，クリストファー
エーデルマン，バート
Original Assignee
ダイアックス コーポレーション
ダイアックス コーポレーション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52993413&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP6757252(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ダイアックス コーポレーション, ダイアックス コーポレーション filed Critical ダイアックス コーポレーション
Publication of JP2016536012A publication Critical patent/JP2016536012A/ja
Publication of JP2016536012A5 publication Critical patent/JP2016536012A5/ja
Application granted granted Critical
Publication of JP6757252B2 publication Critical patent/JP6757252B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/56—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving blood clotting factors, e.g. involving thrombin, thromboplastin, fibrinogen
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21034—Plasma kallikrein (3.4.21.34)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21038—Coagulation factor XIIa (3.4.21.38)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4713—Plasma globulins, lactoglobulin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96433—Serine endopeptidases (3.4.21)
    • G01N2333/96441—Serine endopeptidases (3.4.21) with definite EC number
    • G01N2333/96455—Kallikrein (3.4.21.34; 3.4.21.35)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96433—Serine endopeptidases (3.4.21)
    • G01N2333/96441—Serine endopeptidases (3.4.21) with definite EC number
    • G01N2333/96458—Factor XII (3.4.21.38)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/20—Screening for compounds of potential therapeutic value cell-free systems
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/22—Haematology
    • G01N2800/224—Haemostasis or coagulation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Neurosurgery (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
JP2016549206A 2013-10-21 2014-10-17 血漿カリクレイン系バイオマーカーを決定するためのアッセイ Active JP6757252B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361893505P 2013-10-21 2013-10-21
US61/893,505 2013-10-21
US201461939837P 2014-02-14 2014-02-14
US61/939,837 2014-02-14
PCT/US2014/061247 WO2015061183A1 (en) 2013-10-21 2014-10-17 Assays for determining plasma kallikrein system biomarkers

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020144118A Division JP7135039B2 (ja) 2013-10-21 2020-08-28 血漿カリクレイン系バイオマーカーを決定するためのアッセイ

Publications (3)

Publication Number Publication Date
JP2016536012A JP2016536012A (ja) 2016-11-24
JP2016536012A5 JP2016536012A5 (cg-RX-API-DMAC7.html) 2017-11-24
JP6757252B2 true JP6757252B2 (ja) 2020-09-16

Family

ID=52993413

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2016549206A Active JP6757252B2 (ja) 2013-10-21 2014-10-17 血漿カリクレイン系バイオマーカーを決定するためのアッセイ
JP2020144118A Active JP7135039B2 (ja) 2013-10-21 2020-08-28 血漿カリクレイン系バイオマーカーを決定するためのアッセイ
JP2022137393A Active JP7668772B2 (ja) 2013-10-21 2022-08-31 血漿カリクレイン系バイオマーカーを決定するためのアッセイ
JP2024117419A Pending JP2024150637A (ja) 2013-10-21 2024-07-23 血漿カリクレイン系バイオマーカーを決定するためのアッセイ

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2020144118A Active JP7135039B2 (ja) 2013-10-21 2020-08-28 血漿カリクレイン系バイオマーカーを決定するためのアッセイ
JP2022137393A Active JP7668772B2 (ja) 2013-10-21 2022-08-31 血漿カリクレイン系バイオマーカーを決定するためのアッセイ
JP2024117419A Pending JP2024150637A (ja) 2013-10-21 2024-07-23 血漿カリクレイン系バイオマーカーを決定するためのアッセイ

Country Status (13)

Country Link
US (2) US11372002B2 (cg-RX-API-DMAC7.html)
EP (2) EP3808857B1 (cg-RX-API-DMAC7.html)
JP (4) JP6757252B2 (cg-RX-API-DMAC7.html)
KR (4) KR102521947B1 (cg-RX-API-DMAC7.html)
CN (1) CN105873951A (cg-RX-API-DMAC7.html)
AU (3) AU2014340450B2 (cg-RX-API-DMAC7.html)
BR (1) BR112016008970B1 (cg-RX-API-DMAC7.html)
CA (1) CA2927824C (cg-RX-API-DMAC7.html)
DK (1) DK3060582T3 (cg-RX-API-DMAC7.html)
ES (1) ES2837858T3 (cg-RX-API-DMAC7.html)
IL (3) IL289514B2 (cg-RX-API-DMAC7.html)
PL (1) PL3060582T3 (cg-RX-API-DMAC7.html)
WO (1) WO2015061183A1 (cg-RX-API-DMAC7.html)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3459564T1 (sl) 2010-01-06 2022-06-30 Takeda Pharmaceutical Company Limited Proteini, ki vežejo plazemski kalikrein
JP2014506257A (ja) * 2011-01-06 2014-03-13 ダイアックス コーポレーション 血漿カリクレイン結合タンパク質
EP3456744B1 (en) * 2013-01-20 2023-03-29 Takeda Pharmaceutical Company Limited Evaluation and treatment of bradykinin-mediated disorders
AU2014340450B2 (en) 2013-10-21 2020-05-21 Takeda Pharmaceutical Company Limited Assays for determining plasma kallikrein system biomarkers
US10101344B2 (en) 2013-10-21 2018-10-16 Dyax Corp. Diagnosis and treatment of autoimmune diseases
EA038532B1 (ru) 2014-01-21 2021-09-10 Такеда Фармасьютикал Компани Лимитед Способ лечения наследственного ангионевротического отека (hae)
IL295414B1 (en) 2014-03-27 2025-10-01 Takeda Pharmaceuticals Co Compositions and methods for treating macular edema due to diabetes
EP3286226A4 (en) * 2015-03-30 2018-12-05 Dyax Corp. Plasma kallikrein inhibitors and uses thereof for preventing hereditary angioedema attack
EP3334343B1 (en) * 2015-08-13 2022-10-19 Takeda Pharmaceutical Company Limited Evacuated blood collection tubes containing protease inhibitors for the assessment of contact system activation
PL3365685T3 (pl) * 2015-10-19 2021-08-02 Dyax Corp. Test immunologiczny do wykrywania rozszczepionego wielkocząsteczkowego kininogenu
AU2016372159B2 (en) 2015-12-15 2022-03-24 Takeda Pharmaceutical Company Limited Peptide quantitation assay for differentiating full-length high molecular weight kininogen (HMWK) and cleaved HMWK
IL265195B2 (en) * 2016-09-16 2025-02-01 Dyax Corp Protein biomarkers for diseases related to the activation system
IL315175A (en) * 2016-09-16 2024-10-01 Takeda Pharmaceuticals Co RNA biomarkers for hereditary angioedema
BR112019005167A2 (pt) * 2016-09-16 2019-07-02 Dyax Corp. método e kit para analisar uma amostra
EP3521828A1 (en) * 2018-01-31 2019-08-07 Centogene AG Method for the diagnosis of hereditary angioedema
WO2019165308A1 (en) * 2018-02-22 2019-08-29 The Regents Of The University Of California Threshold-stimulated plasma kallikrein activity as a biomarker for diagnosis of bradykinin-mediated angioedema
CN111057745B (zh) * 2019-12-30 2022-08-12 中国科学院生态环境研究中心 一种物质的血液毒性效应的高通量筛选方法
CN113777331A (zh) * 2020-06-09 2021-12-10 张曼 尿液激肽原-1及其多肽片段在烧伤中的应用
CN114166924B (zh) * 2021-12-03 2024-11-22 中国医学科学院北京协和医院 尿液蛋白标志物在诊断遗传性血管水肿中的用途
JP2025522757A (ja) * 2022-06-30 2025-07-17 武田薬品工業株式会社 ラナデルマブ治療のためのタンパク質バイオマーカー
WO2025153806A1 (en) * 2024-01-15 2025-07-24 Kalvista Pharmaceuticals Limited Methods for determining amidolytic activity

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1312564C (en) * 1985-07-12 1993-01-12 Robert W. Colman Monoclonal antibodies to human plasma prekallikrein and methods of preparing and using same
US5047323A (en) 1986-01-22 1991-09-10 Temple University Of The Commonwealth System Of Higher Education Method for detecting human kininogen using monoclonal antibodies thereto
US4908431A (en) 1986-01-22 1990-03-13 Temple University-Of The Commonwealth System Of Higher Education Monoclonal antibodies to human kininogen and methods of preparing same
US4881175A (en) 1986-09-02 1989-11-14 Genex Corporation Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
KR960009766B1 (ko) 1986-09-10 1996-07-24 니혼 소오끼 세이야꾸 가부시기가이샤 생리 활성물질 측정법
US4882272A (en) 1986-10-01 1989-11-21 Temple University - Of The Commonwealth System Of Higher Education High molecular weight kininogen assay
US5025796A (en) 1988-12-01 1991-06-25 The United States Of America As Represented By The Department Of Health And Human Services Apparatus and methods for determining in vivo response to thermal stimulation in in an unrestrained subject
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
CA2103059C (en) 1991-06-14 2005-03-22 Paul J. Carter Method for making humanized antibodies
US5472945A (en) 1991-08-13 1995-12-05 Temple University- Of The Commonwealth System Of Higher Education Modulation of blood pressure and inhibition of platelet activation with kininogen fragment
US6057287A (en) 1994-01-11 2000-05-02 Dyax Corp. Kallikrein-binding "Kunitz domain" proteins and analogues thereof
ES2227545T3 (es) 1994-01-11 2005-04-01 Dyax Corporation Proteinas y sus analogos del "dominio de kunitz" inhibidores de calicreina.
JPH1084995A (ja) 1996-09-12 1998-04-07 Nippon Zoki Pharmaceut Co Ltd 血液凝固第ｘｉｉ因子活性化法
US5789261A (en) 1996-10-30 1998-08-04 Temple University Of The Commonwealth System Of Higher Education Solid phase immunoassay
US6242210B1 (en) 1997-05-20 2001-06-05 Actinova Limited Treatment of bacterial infections
JP4346798B2 (ja) 1999-08-19 2009-10-21 協和メデックス株式会社 Ｈｃｖコア抗原の検出または定量方法およびそれに用いる検出または定量試薬。
US6994852B1 (en) 1999-11-12 2006-02-07 Temple University-Of The Commonwealth System Of Higher Education Inhibition of angiogenesis by antibodies against high molecular weight kininogen domain 5
US7067713B2 (en) * 2000-01-31 2006-06-27 Pharming Intellectual Property B.V. C1 Inhibitor produced in the milk of transgenic non-human mammals
US7678541B2 (en) 2000-11-21 2010-03-16 Hologic, Inc. Methods and compositions for the detection of a nucleic acid using a non-invasive cleavage reaction
JP2002221519A (ja) 2001-01-29 2002-08-09 Sysmex Corp 抗凝固剤およびそれを用いた抗凝固剤処理方法
US20040152633A1 (en) 2001-05-31 2004-08-05 Jorgensen Marianne Ulrich Kunitz-type sequences and polypeptides
US6913900B2 (en) 2001-08-29 2005-07-05 Nippon Zoki Pharmaceutical Co., Ltd. Plasma prekallikrein activation and kallikrein production assay
DE60333758D1 (de) 2002-06-07 2010-09-23 Dyax Corp Prevention und Verringerung von Ischemia
AU2003281287A1 (en) 2002-07-04 2004-01-23 Oxford Glycosciences (Uk) Ltd Toxicity markers
US20070003552A1 (en) 2002-07-09 2007-01-04 Gebbink Martijn F B Cross-beta structure comprising amyloid binding proteins and methods for detection of the cross-beta structure, for modulating cross-beta structures fibril formation and for modulating cross-beta structure-mediated toxicity and method for interfering with blood coagulation
EP1598428A1 (en) * 2004-05-18 2005-11-23 Georg Dewald Methods and kits to detect Hereditary angioedema type III
JP2008515774A (ja) 2004-08-03 2008-05-15 ダイアックス コーポレイション ｈＫ１結合タンパク質
US7235530B2 (en) 2004-09-27 2007-06-26 Dyax Corporation Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
EP1981519B1 (en) 2005-12-29 2017-12-27 Dyax Corp. Protease inhibition
US7276480B1 (en) 2005-12-30 2007-10-02 Dyax Corp. Prevention and reduction of blood loss
CA2658523C (en) 2006-07-31 2012-06-12 Activesite Pharmaceuticals, Inc. Inhibitors of plasma kallikrein
EP2089712A4 (en) 2006-11-22 2010-09-22 Life Technologies Corp BIOMARKERS OF AUTOIMMUNE DISEASES
WO2009026334A2 (en) 2007-08-21 2009-02-26 Genzyme Corporation Treatment with kallikrein inhibitors
WO2009051259A1 (ja) 2007-10-18 2009-04-23 Miyazaki Prefectural Industrial Support Foundation 肝疾患診断用バイオマーカー
US20110154517A1 (en) * 2007-10-22 2011-06-23 Georg Dewald Disorders of vasoregulation and methods of diagnosing them
KR20110057086A (ko) 2008-07-07 2011-05-31 니폰 조키 세야쿠 가부시키가이샤 섬유근 통증의 검사법
US20110212104A1 (en) 2008-11-03 2011-09-01 Schering Corporation Inflammatory bowel disease biomarkers and related methods of treatment
US20110318359A1 (en) 2008-12-02 2011-12-29 Feener Edward P Method for reducing blood pressure using inhibitors of plasma kallikrein
JP2013516389A (ja) 2009-01-06 2013-05-13 ダイアックス コーポレーション カリクレイン阻害剤による粘膜炎治療
FR2942233B1 (fr) 2009-02-19 2015-03-13 Lfb Biotechnologies Moyens pour la purification d'une proteine du plasma sanguin, et procedes pour sa mise en oeuvre
KR101077275B1 (ko) 2009-05-07 2011-10-27 한국기초과학지원연구원 당단백질의 당쇄화를 이용한 암 진단 방법
JO3244B1 (ar) 2009-10-26 2018-03-08 Amgen Inc بروتينات ربط مستضادات il – 23 البشرية
MX2012006913A (es) 2009-12-18 2012-08-23 Activesite Pharmaceuticals Inc Profarmacos de inhibidores de calicreina plasmatica.
US9206123B2 (en) 2009-12-18 2015-12-08 Activesite Pharmaceuticals, Inc. Prodrugs of inhibitors of plasma kallikrein
SI3459564T1 (sl) 2010-01-06 2022-06-30 Takeda Pharmaceutical Company Limited Proteini, ki vežejo plazemski kalikrein
WO2012009447A2 (en) 2010-07-13 2012-01-19 University Of Rochester THE cAMP/PKA/HDAC5 PATHWAY AND USES THEREOF
EP2645932B1 (en) 2010-12-02 2016-03-02 Becton, Dickinson and Company Blood collection devices containing blood stabilization agent
JP2014506257A (ja) * 2011-01-06 2014-03-13 ダイアックス コーポレーション 血漿カリクレイン結合タンパク質
WO2012170947A2 (en) 2011-06-10 2012-12-13 Isis Pharmaceuticals, Inc. Methods for modulating factor 12 expression
WO2012170945A2 (en) * 2011-06-10 2012-12-13 Isis Pharmaceuticals, Inc. Methods for modulating kallikrein (klkb1) expression
FR2983215B1 (fr) * 2011-11-28 2013-12-20 Univ Grenoble 1 Dosage de la capacite de controle de c1inh
EP3456744B1 (en) 2013-01-20 2023-03-29 Takeda Pharmaceutical Company Limited Evaluation and treatment of bradykinin-mediated disorders
KR20150141940A (ko) 2013-02-01 2015-12-21 벡톤 디킨슨 앤드 컴퍼니 접촉 경로를 저해하는 첨가제를 함유한 채혈 기구
AU2014340450B2 (en) 2013-10-21 2020-05-21 Takeda Pharmaceutical Company Limited Assays for determining plasma kallikrein system biomarkers
US10101344B2 (en) 2013-10-21 2018-10-16 Dyax Corp. Diagnosis and treatment of autoimmune diseases
EA038532B1 (ru) 2014-01-21 2021-09-10 Такеда Фармасьютикал Компани Лимитед Способ лечения наследственного ангионевротического отека (hae)
PL3365685T3 (pl) 2015-10-19 2021-08-02 Dyax Corp. Test immunologiczny do wykrywania rozszczepionego wielkocząsteczkowego kininogenu
AU2016372159B2 (en) 2015-12-15 2022-03-24 Takeda Pharmaceutical Company Limited Peptide quantitation assay for differentiating full-length high molecular weight kininogen (HMWK) and cleaved HMWK
WO2021154992A1 (en) 2020-01-28 2021-08-05 Orgenesis Inc. Process and system for acellular therapy

Also Published As

Publication number Publication date
JP7668772B2 (ja) 2025-04-25
KR102432826B1 (ko) 2022-08-16
IL289514B2 (en) 2024-01-01
EP3060582A4 (en) 2017-07-19
IL289514A (en) 2022-03-01
JP2024150637A (ja) 2024-10-23
CA2927824C (en) 2025-06-17
IL274055A (en) 2020-06-30
CN105873951A (zh) 2016-08-17
AU2014340450B2 (en) 2020-05-21
IL274055B (en) 2022-02-01
CA2927824A1 (en) 2015-04-30
BR112016008970A2 (pt) 2017-09-19
KR20160093604A (ko) 2016-08-08
KR20250066486A (ko) 2025-05-13
BR112016008970B1 (pt) 2023-12-26
AU2014340450A1 (en) 2016-06-02
IL289514B1 (en) 2023-09-01
EP3060582B1 (en) 2020-09-23
IL245205B (en) 2020-05-31
IL245205A0 (en) 2016-06-30
US12442824B2 (en) 2025-10-14
AU2020217316B2 (en) 2024-02-22
KR20230054745A (ko) 2023-04-25
JP2016536012A (ja) 2016-11-24
JP7135039B2 (ja) 2022-09-12
PL3060582T3 (pl) 2021-05-04
JP2021003114A (ja) 2021-01-14
EP3808857B1 (en) 2025-12-10
US20160252527A1 (en) 2016-09-01
EP3808857A1 (en) 2021-04-21
US20220291232A1 (en) 2022-09-15
KR20220119171A (ko) 2022-08-26
KR102521947B1 (ko) 2023-04-14
EP3060582A1 (en) 2016-08-31
US11372002B2 (en) 2022-06-28
WO2015061183A1 (en) 2015-04-30
ES2837858T3 (es) 2021-07-01
JP2022188017A (ja) 2022-12-20
AU2020217316A1 (en) 2020-08-27
AU2024203355A1 (en) 2024-06-06
DK3060582T3 (da) 2020-12-21

Similar Documents

Publication Publication Date Title
JP6757252B2 (ja) 血漿カリクレイン系バイオマーカーを決定するためのアッセイ
JP7441662B2 (ja) ｐＫａｌ関連疾病の評価、アッセイおよび治療
JP6772237B2 (ja) ブラジキニン媒介障害の評価および治療
HK40048781A (en) Assays for determining plasma kallikrein system biomarkers
HK1214361B (en) Evaluation, assays and treatment of pkal-mediated disorders

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171016

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20171016

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20180725

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180807

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20181106

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20181227

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190205

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190806

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20191031

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20191226

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200205

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200804

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200828

R150 Certificate of patent or registration of utility model

Ref document number: 6757252

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250